Drug · DIN 02380242
ZELBORAF
FILM-COATED TABLET
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since March 5, 2012; first marketed March 5, 2012.
- Drug Identification Number (DIN)
- 02380242
- Company (DIN owner)
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Vemurafenib L01EC01
- Class
- Human
- Record last updated
- August 6, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| VEMURAFENIB | 240 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- February 15, 2012: NOC 13039New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “zelboraf”. A notice may cover another product or only some lots: read it to see what it covers.
- ZELBORAF (vemurafenib) - Risk of Radiation Sensitization or Radiation Recall ReactionDecember 22, 2015 · Drugs · Product safety
- Skin-cancer drug Zelboraf (vemurafenib): new warning on the risk of pancreatitisFebruary 12, 2015 · Drugs · New safety information - Product safety
- ZELBORAF (vemurafenib) - Association with Liver Problems - For the PublicApril 7, 2014 · Drugs · Product safety
- ZELBORAF (vemurafenib) - Association with Liver Problems - For Health ProfessionalsApril 7, 2014 · Drugs · Product safety
- ZELBORAF (vemurafenib) - Risk of Progression of Certain Types of Cancer and Risk of Serious Rash - For Health ProfessionalsAugust 20, 2013 · Drugs · Product safety
- ZELBORAF (vemurafenib) - Risk of Progression of Certain Types of Cancer and Risk of Serious Rash - For the PublicAugust 20, 2013 · Drugs · Product safety